Simcere Pharmaceutical Group Limited has released its notice for the 2026 annual general meeting (AGM), scheduled for 9:00 a.m. on 12 June 2026 at No. 800 Minbei Road, Minhang District, Shanghai, PRC.

The ordinary business to be tabled includes the adoption of the audited consolidated financial statements for the year ended 31 December 2025 and the declaration of a final dividend of RMB0.18 per share. If approved, any director will be authorised to execute all matters necessary for dividend distribution.

Directorial changes feature prominently. Shareholders will vote on the re-election of executive directors Mr. Tang Renhong and Mr. Wan Yushan, alongside independent non-executive director Mr. Song Ruilin. The board will also seek authority to determine directors’ remuneration.

Audit continuity is addressed through the proposed re-appointment of KPMG as external auditor, with the board empowered to set the audit fee.

Three share-capital mandates will be presented: 1. An issuance mandate allowing the board to allot and issue shares or securities convertible into shares up to 20 % of the issued share capital during the defined mandate period. 2. A buy-back mandate permitting the company to repurchase up to 10 % of its issued shares. 3. An extension mandate increasing the issuance limit by the number of shares repurchased under the buy-back mandate, capped at a further 10 % of issued share capital.

As special business, the company seeks shareholder approval to adopt amended and restated articles of association, consolidating all proposed amendments detailed in the circular dated 22 May 2026.

Key record dates have been set. The register of members will close from 9 June 2026 to 12 June 2026 (both days inclusive) for AGM attendance eligibility, and from 19 June 2026 to 24 June 2026 (both days inclusive) for entitlement to the proposed final dividend. Share transfers for these purposes must be lodged with Computershare Hong Kong Investor Services Limited by 4:30 p.m. on 8 June 2026 and 18 June 2026 respectively.

The board currently comprises Chairman and Executive Director Mr. Ren Jinsheng, executive directors Mr. Tang Renhong, Mr. Wan Yushan and Ms. Wang Xi, and independent non-executive directors Mr. Song Ruilin, Mr. Wang Jianguo, Mr. Wang Xinhua and Mr. Sung Ka Woon.

Voting at the AGM will be conducted by poll, and results will be published on the websites of the Stock Exchange and Simcere Pharma in accordance with listing rules.